Lethality of BRCA1 or BRCA2 deficiency when combined with PARP1 inhibition or cisplatin is perhaps the most famous of synthetic lethal interactions discovered 133 and translated into the clinic as treatment against breast and ovarian cancer 134, 135. The gene discussed is BRCA2; the disease is ovarian carcinoma.